A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy Volunteers.

Trial Profile

A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Aug 2011 Results from this trial have been published in The Lancet, according to a Cytokinetics media release.
    • 29 Jun 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 22 Jun 2011 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top